biologic

Somavert

pegvisomant

Loss of exclusivityJuly 2026projected — 12-year biologic exclusivity estimate
CompanyPharmacia & Upjohn Company LLC

Drug detail

Brand nameSomavert
Active ingredientpegvisomant
Strength30MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Somavert patent cliff — loss of exclusivity July 2026 | CliffBio